-

02:05:54 AM

CYTO Stock News

CYTO - Altamira Therapeutics Ltd

01/27/23 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Provides Business Update

Process for divestiture / partnering of legacy assets continues Strong data from Bentrio ® NASAR study reinforces its therapeutic benefit for allergic rhinitis Case for Bentrio’s protective effect in viral infection prophylaxis still intact

RHEA-AI

neutral

01/24/23 8:17 AM

Nasdaq : CYTO

clinical triallow float

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal spray comparator NASAR main trial phase completed; full

RHEA-AI

neutral

01/10/23 8:47 AM

Nasdaq : CYTO

conferenceslow float

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Company COO Dr. Pañeda will discuss SemaPhore TM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs other liver-restricted delivery methods

RHEA-AI

very positive

12/19/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Provides Year-End 2022 Business Update

Altamira Therapeutics Provides Year - End 2022 Business Update Strategic Bentrio TM partnering or divestiture process enters decisive phase Partnering or divestiture process for inner ear therapeutics assets ongoing Implementing new

RHEA-AI

neutral

12/02/22 8:47 AM

Nasdaq : CYTO

clinical triallow float

Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated

RHEA-AI

neutral

11/30/22 8:47 AM

Nasdaq : CYTO

earningslow float

Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results

Bentrio TM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergens COVAMID trial with Bentrio in acute COVID-19 progressing towards read-out in December Strategic Bentrio partnering or

RHEA-AI

neutral

11/30/22 8:07 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma

Initiative is Nuance’s first step in penetrating Chinese market with Bentrio TM Densely populated Hong Kong (7.3 million) remains negatively impacted by COVID-19 Nuance Pharma to file for marketing approval in Macao, Mainland China and South

RHEA-AI

neutral

11/22/22 8:47 AM

Nasdaq : CYTO

low float

In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability

• Animal study shows effective protection of mitochondria from oxidative damage and reduced plaque vulnerability in advanced atherosclerosis following treatment with SOD2 mRNA nanoparticles based on Altamira's SemaPhore™ technology • Data presented at American Heart Association Annual Scientific

RHEA-AI

neutral

11/10/22 8:47 AM

Nasdaq : CYTO

conferenceslow float

Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event

• TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria • Company Chief Development Officer, Covadonga Pañeda, Ph.D., to present on the advantages of Altamira’s OligoPhoreTM / SemaPhoreTM RNA delivery technology • Dr.

RHEA-AI

neutral

11/09/22 8:47 AM

Nasdaq : CYTO

low float

Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement

Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today announced that it has regained compliance with the Nasdaq listing requirements. On November 08, 2022 the

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

CYTO Data

IndustryPharmaceutical Preparation Manufacturing
Websitehttp://www.aurismedical.com/
CeoThomas Meyer
Security nameAltamira Therapeutics Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees17
AddressBahnhofstrasse 21
StateZug
CityZug
Zip6300
CountrySwitzerland
Phone41417297194

About Altamira Therapeutics Ltd

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'